Loading clinical trials...
Loading clinical trials...
A Randomized Withdrawal, Active- and Placebo-controlled, Double-blind, Multi-center Phase III Trial Assessing Safety and Efficacy of Oral CG5503 (Tapentadol) Prolonged Release (PR*) in Subjects With Moderate to Severe Chronic Malignant Tumor-related Pain. *Prolonged Release and is the Recommended Nomenclature for Use in the European Union (EU). ER Means Extended Release and is the Recommended Nomenclature for Use in the United States of America (USA). "PR" is Synonymous With "ER" and is Interchangeable.
Conditions
Interventions
Tapentadol in the Titration Phase
Morphine in the Maintenance Phase
+3 more
Locations
37
United States
001013
St. Petersburg, Florida, United States
001002
Elkhart, Indiana, United States
001001
Shreveport, Louisiana, United States
001010
Cedarhurst, New York, United States
001003
Glens Falls, New York, United States
001004
Winston-Salem, North Carolina, United States
Start Date
June 1, 2007
Primary Completion Date
February 1, 2009
Completion Date
May 1, 2009
Last Updated
November 1, 2019
NCT07486219
NCT07336732
NCT07169851
NCT07209111
NCT07213804
NCT07190248
Lead Sponsor
Grünenthal GmbH
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions